Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
109,272,143
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
1,187,087
-
Shares change
-
+217,746
-
Total reported value, excl. options
-
$1,652,710
-
Value change
-
+$287,570
-
Number of buys
-
16
-
Number of sells
-
-8
-
Price
-
$1.4
Significant Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) as of Q4 2021
38 filings reported holding ONCY - ONCOLYTICS BIOTECH INC - Common Stock, no par value as of Q4 2021.
ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,187,087 shares
of 109,272,143 outstanding shares and own 1.09% of the company stock.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (235,478 shares), INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC (173,511 shares), Advisor Resource Council (100,000 shares), CITADEL ADVISORS LLC (95,335 shares), MORGAN STANLEY (87,550 shares), CIBC World Markets Inc. (60,629 shares), TWO SIGMA ADVISERS, LP (42,200 shares), ROYAL BANK OF CANADA (41,476 shares), Long Focus Capital Management, LLC (40,000 shares), and JPMORGAN CHASE & CO (36,235 shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.